nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—trigeminal nerve—peripheral nervous system neoplasm	0.0909	0.283	CbGeAlD
Fosaprepitant—TACR1—vagus nerve—peripheral nervous system neoplasm	0.085	0.265	CbGeAlD
Fosaprepitant—TACR1—cranial nerve—peripheral nervous system neoplasm	0.0648	0.202	CbGeAlD
Fosaprepitant—TACR1—nerve—peripheral nervous system neoplasm	0.0332	0.103	CbGeAlD
Fosaprepitant—TACR1—ganglion—peripheral nervous system neoplasm	0.0328	0.102	CbGeAlD
Fosaprepitant—TACR1—brainstem—peripheral nervous system neoplasm	0.0143	0.0444	CbGeAlD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.00327	0.138	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.00155	0.0654	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.00153	0.0645	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.00139	0.0585	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00103	0.0433	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000942	0.0397	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—BDNF—peripheral nervous system neoplasm	0.000879	0.037	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000863	0.0364	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000782	0.033	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00075	0.0316	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000703	0.0296	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000697	0.0294	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.000688	0.029	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000623	0.0263	CbGpPWpGaD
Fosaprepitant—Constipation—Vincristine—peripheral nervous system neoplasm	0.00051	0.000778	CcSEcCtD
Fosaprepitant—Pain—Vincristine—peripheral nervous system neoplasm	0.00051	0.000778	CcSEcCtD
Fosaprepitant—Osteoarthritis—Doxorubicin—peripheral nervous system neoplasm	0.00051	0.000778	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.00051	0.000778	CcSEcCtD
Fosaprepitant—Rash—Melphalan—peripheral nervous system neoplasm	0.000508	0.000776	CcSEcCtD
Fosaprepitant—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000508	0.000775	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000506	0.000772	CcSEcCtD
Fosaprepitant—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000504	0.000769	CcSEcCtD
Fosaprepitant—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.000503	0.000768	CcSEcCtD
Fosaprepitant—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.000502	0.000765	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000501	0.000764	CcSEcCtD
Fosaprepitant—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000498	0.00076	CcSEcCtD
Fosaprepitant—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000496	0.000757	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.000496	0.000757	CcSEcCtD
Fosaprepitant—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000493	0.000752	CcSEcCtD
Fosaprepitant—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000492	0.000751	CcSEcCtD
Fosaprepitant—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000492	0.00075	CcSEcCtD
Fosaprepitant—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000489	0.000747	CcSEcCtD
Fosaprepitant—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000489	0.000747	CcSEcCtD
Fosaprepitant—Nausea—Topotecan—peripheral nervous system neoplasm	0.000489	0.000746	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000488	0.000744	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000486	0.000742	CcSEcCtD
Fosaprepitant—Muscular weakness—Epirubicin—peripheral nervous system neoplasm	0.000486	0.000742	CcSEcCtD
Fosaprepitant—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000485	0.00074	CcSEcCtD
Fosaprepitant—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000485	0.00074	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000483	0.000737	CcSEcCtD
Fosaprepitant—Infection—Etoposide—peripheral nervous system neoplasm	0.00048	0.000733	CcSEcCtD
Fosaprepitant—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	0.000479	0.000732	CcSEcCtD
Fosaprepitant—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000479	0.000731	CcSEcCtD
Fosaprepitant—Nausea—Melphalan—peripheral nervous system neoplasm	0.000479	0.000731	CcSEcCtD
Fosaprepitant—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000472	0.00072	CcSEcCtD
Fosaprepitant—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000472	0.00072	CcSEcCtD
Fosaprepitant—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.00047	0.000718	CcSEcCtD
Fosaprepitant—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000469	0.000716	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000467	0.000713	CcSEcCtD
Fosaprepitant—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000466	0.000711	CcSEcCtD
Fosaprepitant—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.000464	0.000708	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000461	0.0194	CbGpPWpGaD
Fosaprepitant—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000459	0.000701	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.000459	0.000701	CcSEcCtD
Fosaprepitant—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000458	0.0007	CcSEcCtD
Fosaprepitant—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000457	0.000697	CcSEcCtD
Fosaprepitant—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000456	0.000696	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000455	0.000695	CcSEcCtD
Fosaprepitant—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000451	0.000689	CcSEcCtD
Fosaprepitant—Pain—Cisplatin—peripheral nervous system neoplasm	0.000451	0.000688	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.00045	0.000686	CcSEcCtD
Fosaprepitant—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.00045	0.000686	CcSEcCtD
Fosaprepitant—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000445	0.00068	CcSEcCtD
Fosaprepitant—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000444	0.000678	CcSEcCtD
Fosaprepitant—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000444	0.000677	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000442	0.0186	CbGpPWpGaD
Fosaprepitant—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.00044	0.000671	CcSEcCtD
Fosaprepitant—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000439	0.000671	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—CASP3—peripheral nervous system neoplasm	0.000439	0.0185	CbGpPWpGaD
Fosaprepitant—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000438	0.000668	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000435	0.000663	CcSEcCtD
Fosaprepitant—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000435	0.000663	CcSEcCtD
Fosaprepitant—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000431	0.000658	CcSEcCtD
Fosaprepitant—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000431	0.000657	CcSEcCtD
Fosaprepitant—Somnolence—Etoposide—peripheral nervous system neoplasm	0.00043	0.000655	CcSEcCtD
Fosaprepitant—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000428	0.000653	CcSEcCtD
Fosaprepitant—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000425	0.000648	CcSEcCtD
Fosaprepitant—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000425	0.000648	CcSEcCtD
Fosaprepitant—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000424	0.000648	CcSEcCtD
Fosaprepitant—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000424	0.000646	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000421	0.000642	CcSEcCtD
Fosaprepitant—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000421	0.000642	CcSEcCtD
Fosaprepitant—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.00042	0.000641	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000417	0.000637	CcSEcCtD
Fosaprepitant—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000417	0.000636	CcSEcCtD
Fosaprepitant—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000417	0.000636	CcSEcCtD
Fosaprepitant—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000414	0.000632	CcSEcCtD
Fosaprepitant—Pain—Etoposide—peripheral nervous system neoplasm	0.000413	0.000631	CcSEcCtD
Fosaprepitant—Constipation—Etoposide—peripheral nervous system neoplasm	0.000413	0.000631	CcSEcCtD
Fosaprepitant—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000413	0.00063	CcSEcCtD
Fosaprepitant—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000413	0.00063	CcSEcCtD
Fosaprepitant—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000412	0.000629	CcSEcCtD
Fosaprepitant—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000409	0.000625	CcSEcCtD
Fosaprepitant—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000408	0.000623	CcSEcCtD
Fosaprepitant—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000407	0.000621	CcSEcCtD
Fosaprepitant—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000405	0.000618	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000402	0.000614	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000401	0.0169	CbGpPWpGaD
Fosaprepitant—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000399	0.000608	CcSEcCtD
Fosaprepitant—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000398	0.000608	CcSEcCtD
Fosaprepitant—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000397	0.000605	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000395	0.000603	CcSEcCtD
Fosaprepitant—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000394	0.000602	CcSEcCtD
Fosaprepitant—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000394	0.000601	CcSEcCtD
Fosaprepitant—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000393	0.0006	CcSEcCtD
Fosaprepitant—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000393	0.0006	CcSEcCtD
Fosaprepitant—Rash—Alitretinoin—peripheral nervous system neoplasm	0.00039	0.000596	CcSEcCtD
Fosaprepitant—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.00039	0.000595	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.00039	0.000594	CcSEcCtD
Fosaprepitant—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000389	0.000593	CcSEcCtD
Fosaprepitant—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000388	0.000592	CcSEcCtD
Fosaprepitant—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000388	0.000592	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000385	0.0162	CbGpPWpGaD
Fosaprepitant—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000384	0.000586	CcSEcCtD
Fosaprepitant—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	0.000383	0.000584	CcSEcCtD
Fosaprepitant—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000382	0.000583	CcSEcCtD
Fosaprepitant—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000382	0.000583	CcSEcCtD
Fosaprepitant—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000382	0.000583	CcSEcCtD
Fosaprepitant—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000382	0.000583	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000379	0.000579	CcSEcCtD
Fosaprepitant—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000379	0.000579	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000379	0.016	CbGpPWpGaD
Fosaprepitant—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000378	0.000577	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000376	0.000575	CcSEcCtD
Fosaprepitant—Rash—Vincristine—peripheral nervous system neoplasm	0.000376	0.000574	CcSEcCtD
Fosaprepitant—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000376	0.000573	CcSEcCtD
Fosaprepitant—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000375	0.000572	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000375	0.000572	CcSEcCtD
Fosaprepitant—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000374	0.00057	CcSEcCtD
Fosaprepitant—Headache—Vincristine—peripheral nervous system neoplasm	0.000374	0.00057	CcSEcCtD
Fosaprepitant—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000368	0.000561	CcSEcCtD
Fosaprepitant—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000361	0.000551	CcSEcCtD
Fosaprepitant—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.00036	0.00055	CcSEcCtD
Fosaprepitant—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000359	0.000548	CcSEcCtD
Fosaprepitant—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000356	0.000544	CcSEcCtD
Fosaprepitant—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000356	0.000543	CcSEcCtD
Fosaprepitant—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000355	0.000542	CcSEcCtD
Fosaprepitant—Nausea—Vincristine—peripheral nervous system neoplasm	0.000354	0.000541	CcSEcCtD
Fosaprepitant—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000354	0.00054	CcSEcCtD
Fosaprepitant—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000354	0.00054	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000351	0.0148	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000351	0.0148	CbGpPWpGaD
Fosaprepitant—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000351	0.000536	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000348	0.000532	CcSEcCtD
Fosaprepitant—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000347	0.000529	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000347	0.000529	CcSEcCtD
Fosaprepitant—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000346	0.000528	CcSEcCtD
Fosaprepitant—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000346	0.000528	CcSEcCtD
Fosaprepitant—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000344	0.000525	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000344	0.000524	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—MYC—peripheral nervous system neoplasm	0.000343	0.0144	CbGpPWpGaD
Fosaprepitant—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000342	0.000522	CcSEcCtD
Fosaprepitant—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000335	0.000512	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000335	0.0141	CbGpPWpGaD
Fosaprepitant—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000334	0.00051	CcSEcCtD
Fosaprepitant—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000334	0.000509	CcSEcCtD
Fosaprepitant—Rash—Cisplatin—peripheral nervous system neoplasm	0.000333	0.000507	CcSEcCtD
Fosaprepitant—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000332	0.000507	CcSEcCtD
Fosaprepitant—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000332	0.000506	CcSEcCtD
Fosaprepitant—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000332	0.000506	CcSEcCtD
Fosaprepitant—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000331	0.000504	CcSEcCtD
Fosaprepitant—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.00033	0.000503	CcSEcCtD
Fosaprepitant—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000329	0.000502	CcSEcCtD
Fosaprepitant—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000327	0.0005	CcSEcCtD
Fosaprepitant—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000327	0.0005	CcSEcCtD
Fosaprepitant—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000327	0.000499	CcSEcCtD
Fosaprepitant—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000325	0.000496	CcSEcCtD
Fosaprepitant—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.00032	0.000488	CcSEcCtD
Fosaprepitant—Dizziness—Etoposide—peripheral nervous system neoplasm	0.00032	0.000488	CcSEcCtD
Fosaprepitant—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000319	0.000487	CcSEcCtD
Fosaprepitant—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000319	0.000486	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000318	0.000485	CcSEcCtD
Fosaprepitant—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000313	0.000478	CcSEcCtD
Fosaprepitant—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000309	0.000472	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000308	0.00047	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000307	0.013	CbGpPWpGaD
Fosaprepitant—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000307	0.000469	CcSEcCtD
Fosaprepitant—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000307	0.000469	CcSEcCtD
Fosaprepitant—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000307	0.000469	CcSEcCtD
Fosaprepitant—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000307	0.000468	CcSEcCtD
Fosaprepitant—Rash—Etoposide—peripheral nervous system neoplasm	0.000305	0.000465	CcSEcCtD
Fosaprepitant—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000304	0.000464	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000304	0.0128	CbGpPWpGaD
Fosaprepitant—Headache—Etoposide—peripheral nervous system neoplasm	0.000303	0.000462	CcSEcCtD
Fosaprepitant—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000303	0.000462	CcSEcCtD
Fosaprepitant—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000301	0.000459	CcSEcCtD
Fosaprepitant—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000299	0.000457	CcSEcCtD
Fosaprepitant—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000298	0.000454	CcSEcCtD
Fosaprepitant—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000295	0.000451	CcSEcCtD
Fosaprepitant—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000293	0.000448	CcSEcCtD
Fosaprepitant—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000292	0.000445	CcSEcCtD
Fosaprepitant—Cough—Epirubicin—peripheral nervous system neoplasm	0.00029	0.000442	CcSEcCtD
Fosaprepitant—Nausea—Etoposide—peripheral nervous system neoplasm	0.000287	0.000438	CcSEcCtD
Fosaprepitant—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000287	0.000437	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000285	0.000435	CcSEcCtD
Fosaprepitant—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000284	0.000433	CcSEcCtD
Fosaprepitant—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000283	0.000431	CcSEcCtD
Fosaprepitant—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000282	0.00043	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	0.000282	0.0119	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000281	0.0118	CbGpPWpGaD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000281	0.000428	CcSEcCtD
Fosaprepitant—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000279	0.000426	CcSEcCtD
Fosaprepitant—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000277	0.000423	CcSEcCtD
Fosaprepitant—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000276	0.000422	CcSEcCtD
Fosaprepitant—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000275	0.00042	CcSEcCtD
Fosaprepitant—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000271	0.000414	CcSEcCtD
Fosaprepitant—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000271	0.000413	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000271	0.000413	CcSEcCtD
Fosaprepitant—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.00027	0.000412	CcSEcCtD
Fosaprepitant—Infection—Epirubicin—peripheral nervous system neoplasm	0.000269	0.000411	CcSEcCtD
Fosaprepitant—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000268	0.000409	CcSEcCtD
Fosaprepitant—Shock—Epirubicin—peripheral nervous system neoplasm	0.000266	0.000407	CcSEcCtD
Fosaprepitant—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000266	0.000405	CcSEcCtD
Fosaprepitant—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000265	0.000405	CcSEcCtD
Fosaprepitant—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000263	0.000401	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000262	0.0004	CcSEcCtD
Fosaprepitant—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000261	0.000399	CcSEcCtD
Fosaprepitant—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000261	0.000398	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.00026	0.000396	CcSEcCtD
Fosaprepitant—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000258	0.000394	CcSEcCtD
Fosaprepitant—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000256	0.00039	CcSEcCtD
Fosaprepitant—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000253	0.000386	CcSEcCtD
Fosaprepitant—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000251	0.000382	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000251	0.000382	CcSEcCtD
Fosaprepitant—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000249	0.00038	CcSEcCtD
Fosaprepitant—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000247	0.000376	CcSEcCtD
Fosaprepitant—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000246	0.000375	CcSEcCtD
Fosaprepitant—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000245	0.000374	CcSEcCtD
Fosaprepitant—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000243	0.000371	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000242	0.00037	CcSEcCtD
Fosaprepitant—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000241	0.000368	CcSEcCtD
Fosaprepitant—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000241	0.000367	CcSEcCtD
Fosaprepitant—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000238	0.000364	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000237	0.00999	CbGpPWpGaD
Fosaprepitant—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000235	0.000359	CcSEcCtD
Fosaprepitant—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000234	0.000357	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000234	0.000357	CcSEcCtD
Fosaprepitant—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000234	0.000356	CcSEcCtD
Fosaprepitant—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000232	0.000353	CcSEcCtD
Fosaprepitant—Pain—Epirubicin—peripheral nervous system neoplasm	0.000232	0.000353	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	0.000228	0.0096	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000227	0.00958	CbGpPWpGaD
Fosaprepitant—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000227	0.000346	CcSEcCtD
Fosaprepitant—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000223	0.000341	CcSEcCtD
Fosaprepitant—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000223	0.000341	CcSEcCtD
Fosaprepitant—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000223	0.00034	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000221	0.000338	CcSEcCtD
Fosaprepitant—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000221	0.000337	CcSEcCtD
Fosaprepitant—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000218	0.000332	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000216	0.00033	CcSEcCtD
Fosaprepitant—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000216	0.00033	CcSEcCtD
Fosaprepitant—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000215	0.000328	CcSEcCtD
Fosaprepitant—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000214	0.000327	CcSEcCtD
Fosaprepitant—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000214	0.000327	CcSEcCtD
Fosaprepitant—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000214	0.000327	CcSEcCtD
Fosaprepitant—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000214	0.000327	CcSEcCtD
Fosaprepitant—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000315	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000205	0.000313	CcSEcCtD
Fosaprepitant—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.0002	0.000305	CcSEcCtD
Fosaprepitant—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000304	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000199	0.00837	CbGpPWpGaD
Fosaprepitant—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000198	0.000302	CcSEcCtD
Fosaprepitant—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000198	0.000302	CcSEcCtD
Fosaprepitant—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000194	0.000297	CcSEcCtD
Fosaprepitant—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000192	0.000292	CcSEcCtD
Fosaprepitant—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000185	0.000283	CcSEcCtD
Fosaprepitant—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000185	0.000282	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.00018	0.0076	CbGpPWpGaD
Fosaprepitant—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.00018	0.000274	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.00018	0.00757	CbGpPWpGaD
Fosaprepitant—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000179	0.000273	CcSEcCtD
Fosaprepitant—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000177	0.000271	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000174	0.00732	CbGpPWpGaD
Fosaprepitant—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000172	0.000263	CcSEcCtD
Fosaprepitant—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000171	0.000262	CcSEcCtD
Fosaprepitant—Rash—Epirubicin—peripheral nervous system neoplasm	0.000171	0.000261	CcSEcCtD
Fosaprepitant—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000171	0.00026	CcSEcCtD
Fosaprepitant—Headache—Epirubicin—peripheral nervous system neoplasm	0.00017	0.000259	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	0.000167	0.00702	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000166	0.00699	CbGpPWpGaD
Fosaprepitant—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000166	0.000253	CcSEcCtD
Fosaprepitant—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000161	0.000246	CcSEcCtD
Fosaprepitant—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000159	0.000243	CcSEcCtD
Fosaprepitant—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.000241	CcSEcCtD
Fosaprepitant—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.000241	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000158	0.00665	CbGpPWpGaD
Fosaprepitant—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.00024	CcSEcCtD
Fosaprepitant—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000149	0.000227	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000125	0.00525	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.00011	0.00462	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000107	0.00449	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000102	0.00428	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.32e-05	0.00393	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.59e-05	0.00278	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.47e-05	0.00273	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.12e-05	0.00216	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.82e-05	0.00203	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.69e-05	0.00198	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.64e-05	0.00196	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.26e-05	0.00179	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.89e-05	0.00164	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.63e-05	0.00153	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.98e-05	0.00126	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.85e-05	0.0012	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.51e-05	0.00106	CbGpPWpGaD
